NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis

OSL:NYKD • NO0010714785

2.894 NOK
-0.27 (-8.48%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Overall NYKD gets a fundamental rating of 3 out of 10. We evaluated NYKD against 77 industry peers in the Biotechnology industry. While NYKD seems to be doing ok healthwise, there are quite some concerns on its profitability. NYKD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NYKD has reported negative net income.
  • In the past year NYKD has reported a negative cash flow from operations.
  • In the past 5 years NYKD reported 4 times negative net income.
  • In multiple years NYKD reported negative operating cash flow during the last 5 years.
NYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFNYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • NYKD's Return On Assets of -10.41% is fine compared to the rest of the industry. NYKD outperforms 67.53% of its industry peers.
  • The Return On Equity of NYKD (-11.09%) is better than 72.73% of its industry peers.
Industry RankSector Rank
ROA -10.41%
ROE -11.09%
ROIC N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
NYKD.OL Yearly ROA, ROE, ROICNYKD.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYKD.OL Yearly Profit, Operating, Gross MarginsNYKD.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NYKD has about the same amout of shares outstanding than it did 1 year ago.
  • NYKD has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for NYKD has been reduced compared to a year ago.
NYKD.OL Yearly Shares OutstandingNYKD.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NYKD.OL Yearly Total Debt VS Total AssetsNYKD.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 10.08 indicates that NYKD is not in any danger for bankruptcy at the moment.
  • NYKD has a Altman-Z score of 10.08. This is amongst the best in the industry. NYKD outperforms 89.61% of its industry peers.
  • NYKD has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • NYKD has a Debt to Equity ratio of 0.02. This is in the better half of the industry: NYKD outperforms 76.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 10.08
ROIC/WACCN/A
WACC8.54%
NYKD.OL Yearly LT Debt VS Equity VS FCFNYKD.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • NYKD has a Current Ratio of 17.14. This indicates that NYKD is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 17.14, NYKD belongs to the best of the industry, outperforming 98.70% of the companies in the same industry.
  • A Quick Ratio of 17.14 indicates that NYKD has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 17.14, NYKD belongs to the top of the industry, outperforming 98.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.14
Quick Ratio 17.14
NYKD.OL Yearly Current Assets VS Current LiabilitesNYKD.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • NYKD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.18%.
  • Looking at the last year, NYKD shows a very strong growth in Revenue. The Revenue has grown by 72.62%.
  • The Revenue for NYKD have been decreasing by -36.54% on average. This is quite bad
EPS 1Y (TTM)-0.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, NYKD will show a very negative growth in Earnings Per Share. The EPS will decrease by -66.63% on average per year.
  • Based on estimates for the next years, NYKD will show a very strong growth in Revenue. The Revenue will grow by 184.95% on average per year.
EPS Next Y70.24%
EPS Next 2Y18.52%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NYKD.OL Yearly Revenue VS EstimatesNYKD.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
NYKD.OL Yearly EPS VS EstimatesNYKD.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NYKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NYKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYKD.OL Price Earnings VS Forward Price EarningsNYKD.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYKD.OL Per share dataNYKD.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NYKD's earnings are expected to grow with 14.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.52%
EPS Next 3Y14.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • NYKD has a Yearly Dividend Yield of 25.75%, which is a nice return.
  • NYKD's Dividend Yield is rather good when compared to the industry average which is at 0.47. NYKD pays more dividend than 100.00% of the companies in the same industry.
  • NYKD's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 25.75%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y18.52%
EPS Next 3Y14.21%
NYKD.OL Yearly Income VS Free CF VS DividendNYKD.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

NYKODE THERAPEUTICS ASA

OSL:NYKD (2/27/2026, 7:00:00 PM)

2.894

-0.27 (-8.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)02-25
Inst Owners12.46%
Inst Owner ChangeN/A
Ins Owners1.64%
Ins Owner ChangeN/A
Market Cap945.04M
Revenue(TTM)6.77M
Net Income(TTM)-11.01M
Analysts42.22
Price Target2.24 (-22.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 25.75%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-57.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.6
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0.2
BVpS2.91
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.41%
ROE -11.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.22%
Cap/Sales 1.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.14
Quick Ratio 17.14
Altman-Z 10.08
F-Score5
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)80.08%
Cap/Depr(5y)78.32%
Cap/Sales(3y)17.63%
Cap/Sales(5y)11.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
EPS Next Y70.24%
EPS Next 2Y18.52%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
EBIT growth 1Y55.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.65%
EBIT Next 3Y18.13%
EBIT Next 5Y-60.17%
FCF growth 1Y43.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

NYKODE THERAPEUTICS ASA / NYKD.OL FAQ

What is the ChartMill fundamental rating of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL.


What is the valuation status of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to NYKODE THERAPEUTICS ASA (NYKD.OL). This can be considered as Overvalued.


What is the profitability of NYKD stock?

NYKODE THERAPEUTICS ASA (NYKD.OL) has a profitability rating of 1 / 10.


What is the earnings growth outlook for NYKODE THERAPEUTICS ASA?

The Earnings per Share (EPS) of NYKODE THERAPEUTICS ASA (NYKD.OL) is expected to grow by 70.24% in the next year.